RECRUITING

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.

Official Title

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Quick Facts

Study Start:2024-03-07

Study Completion:2099-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06562270

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 17 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Not specified

Standard Ages:CHILD

Inclusion Criteria	Exclusion Criteria
1. Has ever been diagnosed with severe AA by a dermatologist or a qualified dermatology provider. 2. Is 12-17 years of age at the time of enrollment. 3. Is willing to provide consent/assent for participation in the registry. 4. Has been prescribed a new commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents in the context of routine clinical care that is consistent with local prescribing guidelines and/or regulations for the country where the site is located. 1. At the time of registry enrollment OR 2. Within 6 months prior to registry enrollment In the opinion of the treating provider, is deemed a candidate for treatment with a commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents but has not received nor is planning to initiate treatment at the time of registry enrollment.	1. Is participating or planning to participate in a blinded clinical trial for any investigational medication. 2. Is unwilling or unable to provide standing height measurements.

Inclusion Criteria

Exclusion Criteria

1. Has ever been diagnosed with severe AA by a dermatologist or a qualified dermatology provider.
2. Is 12-17 years of age at the time of enrollment.
3. Is willing to provide consent/assent for participation in the registry.
4. Has been prescribed a new commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents in the context of routine clinical care that is consistent with local prescribing guidelines and/or regulations for the country where the site is located.
1. At the time of registry enrollment OR
2. Within 6 months prior to registry enrollment In the opinion of the treating provider, is deemed a candidate for treatment with a commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents but has not received nor is planning to initiate treatment at the time of registry enrollment.

1. Is participating or planning to participate in a blinded clinical trial for any investigational medication.
2. Is unwilling or unable to provide standing height measurements.

Contacts and Locations

Study Contact

CorEvitas

CONTACT

Study Locations (Sites)

CorEvitas, LLC

Waltham, Massachusetts, 02451

United States

Collaborators and Investigators

Sponsor: CorEvitas

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-07

Study Completion Date2099-12-31

Study Record Updates

Study Start Date2024-03-07

Study Completion Date2099-12-31

Terms related to this study

Additional Relevant MeSH Terms

Alopecia Areata